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ABSTRACT
Lixisenatide (AVE0010) is a once-daily glucagon-
like peptide-1 (GLP-1) receptor agonist used in
the treatment of type 2 diabetes. Phase II dose-
finding and pharmacodynamic studies
identified the 20 lg once-daily dose as having
the optimum combination of efficacy,
convenience and tolerability. Lixisenatide was
prospectively investigated in a series of 11
multinational, randomised, controlled phase III
trials (GLP-1 agonist AVE0010 in paTients with
type 2 diabetes mellitus for Glycemic cOntrol
and sAfety evaLuation [GetGoal] programme)
that included a direct head-to-head study with
exenatide. The GetGoal programme established
the efficacy and safety profile of lixisenatide
20 lg once daily across the spectrum of patients
with type 2 diabetes, including patients not
treated with anti-diabetic agents, those failing
on oral agents and as an adjunct to basal insulin
therapy. The main efficacy endpoints were met
in all studies, with the baseline to endpoint
reductions in HbA1c consistently ranging from
0.7% to 1.0%. In a head-to-head comparison
with exenatide 10 lg twice daily, lixisenatide
20 lg once daily was non-inferior for HbA1c
reduction, achieved with threefold fewer
patients with symptomatic hypoglycemia
events and better gastrointestinal tolerability.
Three randomised trials of lixisenatide
treatment added to basal insulin showed
significantly improved glycemic control over
placebo, with pronounced postprandial glucose
reductions and good tolerability.
Discontinuations for adverse events were
consistently low, ranging from 2.5% to 10.4%.
As the provision of individualized care moves
center stage in diabetes management,
lixisenatide with once-daily dosing, a single
maintenance dose and fixed-dose pens offers
an important treatment option for type 2
diabetes.
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INTRODUCTION
In the last decade, there has been considerable
change in the number and type of
pharmacotherapies available for type 2 diabetes.
One of the most significant advances has been an
improved understanding of the incretin effect and
its role in the pathophysiology of type 2 diabetes,
which has led to the development of a number of
new glucose-lowering agents within the incretin
class [1]. Both glucagon-like peptide-1 receptor
(GLP-1R) agonists and dipeptidyl peptidase-4
(DPP4) inhibitors are now licensed and used
routinely in the management of type 2 diabetes
[1]. Given the positive impact of GLP-1R agonists
on a number of the pathophysiological traits of
type 2 diabetes, including clinically significant
reductions in body weight, this class of drug
continues to expand with new analogs in
development [1].
Currently, four GLP-1R agonists—exenatide
(both as a twice-daily (BD) and once-weekly
(QW) long-acting release (LAR) formulation),
liraglutide, and lixisenatide—are available as
treatments for type 2 diabetes (Fig. 1). Exenatide
is an identical synthetic version of exendin-4, a
GLP-1-like peptide isolated from the saliva of
the Gila monster lizard Heloderma suspectum
that exhibits 53% amino acid identity with
human GLP-1 and is a potent agonist of the
human GLP-1R [2]. Exenatide has a terminal
half-life of *2.4 h and is administered BD
subcutaneously [3]. A long-acting release
formulation, exenatide-LAR, delivers the drug
in microspheres of a biodegradable polymer
resulting in a prolonged half-life and allowing
once-weekly administration, is also approved
[4]. This formulation has been shown to provide
better glycemic control than conventional
exenatide BD over 52 weeks [5].
Liraglutide is an analog of human GLP-1,
modified by a Ser34Arg amino acid substitution
and with the addition of a Glu-spaced fatty acid
chain through the e-amino group of Lys at
position 26 [1]. These modifications alter the
tertiary structure of the molecule, stabilizing
liraglutide against DPP-4 degradation and
allowing it to self-associate and reversibly bind
to serum albumin, creating a circulating
reservoir of drug [1]. These changes result in
decreased clearance and protracted activity,
with a half-life of 13 h suitable for once-daily
(OD) subcutaneous administration [6].
Liraglutide was approved for clinical use in
Europe in 2009 and in the USA in 2010.
Lixisenatide (AVE0010) is the fourth GLP-1R
agonist to be licensed for the treatment of type
2 diabetes. Like exenatide, the 44-amino acid
peptide is based on the structure of exendin-4,
with modifications consisting of a deletion of a
proline residue and addition of six lysine
residues at the C terminal (Fig. 2) [7]. The
in vivo half-life of lixisenatide (20 lg OD) is
3 h [8]. Lixisenatide OD is indicated for the
treatment of adults with type 2 diabetes to
achieve glycemic control in combination with
oral glucose-lowering drugs and/or basal insulin
when these, together with diet and exercise, do
not provide adequate glycemic control.
Although these GLP-1R agonists act through
the same receptor, differences in their
pharmacokinetics—namely short-acting or
Fig. 1 GLP-1 receptor agonists grouped according to
peptide sequence and dosing frequency. GLP-1 receptor
agonists grouped as ‘GLP-1 like’ or ‘exendin-4 like’ and
long-acting (red) or short-acting (blue) with dosing (OD
once daily, BD twice daily); LAR long-acting release
368 Diabetes Ther (2014) 5:367–383
long-acting—manifest as distinct physiological
profiles, in particular distinct gastric emptying
and insulin secretion profiles in the post-meal
period [9]. Short-acting agents (exenatide and
lixisenatide) induce gastric emptying delay in a
similar way to native GLP-1 and blunt
postprandial glucose (PPG) excursions. For
long-acting agents (e.g., liraglutide),
continuous agonism of the GLP-1 receptor
results in a desensitization of the gastric
emptying effect and, in the postprandial
period, the primary glucose-lowering action is
mediated by stimulation of insulin secretion
and glucagon suppression [9]. This article
describes the clinical development program
for the use of lixisenatide in the treatment of
type 2 diabetes and identifies features of
lixisenatide that distinguish it from other
GLP-1R agonists.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
CLINICAL DEVELOPMENT
PROGRAM OF LIXISENATIDE
Phase II Dose-Finding Study
The dose–response effect of lixisenatide was
evaluated in a large group (n = 542) of
metformin-treated patients with type 2
diabetes using OD or twice-daily (BD)
lixisenatide regimens (5–30 lg OD or BD) [10].
At inclusion, patients had been treated with
metformin monotherapy for C3 months but
had suboptimal glycemic control (defined as
glycated hemoglobin [HbA1c] C53 mmol/mol
[7.0%] and \75 mmol/mol [9.0%]). Patients
were randomised to 12 treatment regimens
(eight lixisenatide and four volume-matched
placebo groups) given OD within 1 h before
breakfast or BD within 1 h before breakfast and
dinner for 13 weeks of treatment. The doses in
the 20 and 30 lg lixisenatide groups were
increased in 5 lg/week increments to achieve
the treatment dose in weeks 2–4. The primary
endpoint was change in HbA1c from baseline.
The patients enrolled had relatively well-
controlled diabetes (mean HbA1c of 58 mmol/
mol [7.5%]) with a mean duration of disease of
6.5 years [10]. At week 13, significant, dose-
dependent reductions in HbA1c (the primary
endpoint) were reported [10]. OD and BD
lixisenatide regimens achieved similar HbA1c
reductions, with twice-daily dosing failing to
provide any relevant additional improvement
compared with once-daily regimens. Further
increases in dose beyond 20 lg OD provided
limited benefit relative to the increase in drug
exposure that was accompanied by increased
gastrointestinal adverse events. This is in
keeping with a previous pharmacodynamic
study that found lixisenatide 20 lg OD and BD
significantly improved HbA1c to a similar extent
compared with placebo over a 4-week treatment
Fig. 2 Peptide sequence of lixisenatide and other GLP-1
receptor agonists. Peptide sequence of native human GLP-
1 (7–37) (a) and the GLP-1 receptor agonists liraglutide
(b), exenatide (c) and lixisenatide (d). Light blue amino
acids represent differences to the sequence of human native
GLP-1. Green amino acids represent differences to the
sequence between exenatide and lixisenatide
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period [8]. In a subgroup of patients, a
standardized meal challenge (breakfast)
performed at baseline and week 13 showed
dose-dependent PPG reductions with all
lixisenatide doses [10].
Anti-lixisenatide antibody formation was a
relatively frequent phenomenon, detected in
the range of 43.1% (10 lg OD group) to 71.2%
(20 lg BD group) [10]. No relevant differences
were reported in terms of safety and efficacy
between the patient populations with antibody-
positive and negative status at study end for all
dose regimens.
The most frequently reported adverse events
were gastrointestinal, primarily nausea, which
was dose dependent. Gastrointestinal adverse
events generally began during the first 5 weeks
of the study and were mild-to-moderate in
intensity. There were no cases of pancreatitis.
Discontinuations due to treatment-emergent
adverse events occurred were low (1.8–11.1%
with OD and 0–14.8% with BD dosing and 1.8%
of patients receiving placebo) [10].
There was no evidence of a dose–response
relationship for symptomatic hypoglycemia
(defined as symptoms consistent with
hypoglycemia, with an accompanying blood
glucose \3.3 mmol/L or prompt recovery with
carbohydrate), with 1–3 events per treatment
group and no episodes of severe hypoglycemia.
On the basis of these findings, the 20 lg OD
dose was chosen for the phase III program
because it appeared to offer the best efficacy-to-
tolerability ratio [10].
Phase II Comparison with Liraglutide
in Patients Insufficiently Controlled
on Metformin
The pharmacodynamic characteristics of
lixisenatide and liraglutide were compared in a
head-to-head, open-label phase II trial of 4-week
duration [11]. Patients (N = 148) with type 2
diabetes with inadequate glycemic control on
metformin (median duration of disease of
6.7 years, mean baseline HbA1c 55–57 mmol/
mol [7.2–7.4%]) were randomised to receive
lixisenatide (initiated at 10 lg OD for 2 weeks
followed by 20 lg OD), or liraglutide (started at
0.6 mg and titrated up to 1.8 mg OD). The
primary outcome, reduction in PPG after a
standardized breakfast meal test, was
significantly greater with lixisenatide (change
from baseline in corrected glucose
AUC0:30-4:30 h on day 28 was 8.6 h mmol/L
greater than liraglutide, p\0.0001). Post-meal
insulin secretion was reduced by lixisenatide
and increased by liraglutide. Of note, glucagon
levels were significantly reduced with
lixisenatide over liraglutide (p\0.05). Markers
of satiety (obestatin, PYY-36 and
oxyntomodulin), which were measured as part
of the trial, have not been reported. Both blood
pressure and heart rate were recorded. Mean
changes in blood pressure were comparable
between the two treatment groups. In
contrast, heart rate measured on day 29 had
decreased (mean of 3.6 beats/min from
baseline) with lixisenatide and increased (5.3
beats/min) with liraglutide, which was
significantly different [11].
The Phase III Clinical Trial Program
The Phase III GLP-1 agonist AVE0010 in
paTients with type 2 diabetes mellitus for
Glycemic cOntrol and sAfety evaLuation
(GetGoal) programme included 11 randomised
trials designed to examine the efficacy and
safety of lixisenatide 20 lg OD across the
spectrum of patients with type 2 diabetes,
including those currently not being treated
with anti-diabetic agents, those failing on oral
agents and as an adjunct to basal insulin
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therapy (Table 1) [12–22]. The program was
largely placebo-controlled, although it
included a head-to-head comparison with
exenatide (GetGoal-X) [12], and an open-label
safety trial of lixisenatide alone conducted for
the regulatory authorities in Japan (GetGoal-
Mono-Japan) [13]. In addition, the efficacy and
safety profile of lixisenatide in combination
with basal insulin was assessed in three
randomised trials [14–16]. More than 5,000
patients were recruited in the GetGoal studies
worldwide. In three trials, one- or two-step dose
increases up to the 20 lg OD treatment dose
were compared [13, 17, 18], and in one trial,
morning and evening dosing of lixisenatide
were compared [19]. In the majority of studies,
patients received metformin, reflecting the
current recommendation for metformin by
NICE and the American Diabetes Association/
European Association for the Study of Diabetes
(ADA/EASD) as first-line therapy [23, 24]. Data
from the 11 GetGoal trials have been published,
or presented at international conferences
(summarized in Table 1).
Lixisenatide Monotherapy
GetGoal-Mono was a 12-week, double-blind,
placebo-controlled trial that randomised 361
patients with type 2 diabetes of mean duration
1.1–1.4 years attempting to control their
diabetes with diet and exercise alone, to
lixisenatide OD for 12 weeks as a one-step dose
increase (10 lg for 2 weeks, then 20 lg) or two-
step dose increase (10 lg for 1 week, 15 lg for
1 week, then 20 lg), or placebo also with a one-
or two-step increase [17]. HbA1c was improved
in both dose escalation groups compared with
placebo, with a numerically larger reduction in
those with a single-dose increase (least squares
mean reduction of 0.66% with one-step and
0.54% with two-step, p\0.0001). Significantly,
more patients achieved the HbA1c goal of \7%
with lixisenatide than placebo (47–52% vs.
27%, respectively).
A subgroup of 169 patients took a
standardized meal test at baseline and week
12; 2-h PPG and 2-h plasma glucose excursions
(defined as 2-h PPG minus plasma glucose
30 min prior to the meal test before study drug
administration) were significantly improved
compared with placebo [17]. The PPG values
were markedly reduced by 4.5–5.5 mmol/L
compared with 0.7 mmol/L with placebo, and
similar reductions in the glucose excursion
values were apparent.
Lixisenatide OD was well tolerated; the most
frequent adverse events were gastrointestinal
(mainly nausea with low rates of vomiting and
diarrhea) [17]. The rates of nausea and of
discontinuation because of adverse events
were similar with the two-step and one-step
dose increases. Average body weight reductions
of 2 kg were reported in both lixisenatide and
placebo groups, reflecting a marked placebo
effect in some patients receiving an inactive
injection.
In GetGoal-Mono Japan, Japanese patients
experienced a 0.74% and 0.99% reduction in
HbA1c (one-step or two-step dose increase,
respectively) at week 24, which was sustained
at week 76 (reduction of 0.72% across both
groups) from a baseline HbA1c of 66 mmol/mol
(8.2%). This small, open-label safety study
performed for the regulatory authorities in
Japan reported nausea as the most commonly




GetGoal-M assessed the efficacy and safety of
morning or evening injections of lixisenatide in
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a blinded, placebo-controlled study in patients
inadequately controlled on metformin [19].
Lixisenatide OD morning or evening
significantly improved glycemic control
measured as reduction in HbA1c (reduced by
0.5% and 0.4% over placebo, p\0.0001,
respectively) and proportion achieving target
HbA1c \53 mmol/mol (7.0%) (43% and 40.6%
vs. 22%, p\0.0001, respectively). After a
standardized meal test for those receiving
morning treatment, lixisenatide had a
pronounced effect on 2-h PPG, with a
difference of -4.5 mmol/L (p\0.0001) over
placebo, and on glucose excursion, with a
difference of -3.9 mmol/L over placebo. GI
disturbance was the most common adverse
event; nausea and vomiting occurred in 22.7%
and 9.4% of the morning and 21.2% and 13.3%
of the evening group, respectively.
Symptomatic hypoglycemia was uncommon
(2.4% and 5.1%, respectively) and no severe
events were recorded [19].
GetGoal-M-Asia [20], conducted in China,
Malaysia, Thailand, and Hong Kong,
randomised patients with mean disease
duration of C6.5 years and baseline HbA1c of
62–63 mmol/mol (7.85–7.95%) to lixisenatide
20 lg OD (one-step dose increase) or placebo
[20]. The HbA1c reduction versus placebo at
week 24 was 0.36% (p = 0.0004), with a
pronounced effect on PPG after a standardized
breakfast meal test (lixisenatide associated with
a 4.28 mmol/L reduction compared with
placebo (p\0.0001)). Nausea and vomiting
occurred in 16.3% and 7.7% with lixisenatide.
There were few cases of symptomatic
hypoglycemia [20].
GetGoal-F1 randomised 484 patients with
mean diabetes duration of around 6 years
inadequately controlled on metformin alone
(mean HbA1c of 64 mmol/mol [8%]) in a
double-blind, placebo-controlled trial with a
24-week treatment period [18], followed by an
extension of at least 52 weeks. Patients were
randomised to one of four treatment schedules
to include a one-step or two-step dose
escalation, as per GetGoal-Mono [17].
HbA1c was again improved in both dose
escalation groups compared with placebo
(least squares mean reduction of 0.5% [95% CI
-0.7% to -0.3%] with one-step and 0.4% [95%
CI -0.6% to -0.2%] with two-step, p\0.0001)
[18]. Significantly more patients achieved HbA1c
\53 mmol/mol (7%) with lixisenatide than
placebo (42.1–47.4% vs. 24.1%, respectively) at
24 weeks. The efficacy of lixisenatide was
maintained during the variable extension
period (at week 76: -0.9% for one-step, -0.9%
for two-step and -0.6% for combined placebo).
The proportion of participants achieving HbA1c
targets of \53 mmol/mol (\7 %) and
B48 mmol/mol (B6.5%) were 53.5% and
34.3% for lixisenatide one-step, 49.5 and
25.7% for lixisenatide two-step and 41.8% and
22.8% for the combined placebo, respectively.
Weight reduction was significantly greater with
both lixisenatide 1-step (-2.6 kg) and 2-step
(-2.7 kg) dose increases than placebo (-1.6 kg,
p\0.01 for both comparisons) [18].
At week 24, nausea was the most frequent
adverse event (26.1–35.4%). Symptomatic
hypoglycemia (defined as symptoms consistent
with hypoglycemia, with an accompanying
blood glucose \3.3 mmol/L or prompt
recovery with carbohydrate) occurred
infrequently in all arms of the study (B2.5%);
no severe hypoglycemic events were reported.
In the extension study, the most frequently
reported AEs were nausea and vomiting, with
few discontinuations. Symptomatic
hypoglycemia remained uncommon
(3.7–7.5%), with a similar proportion of
patients with events in the placebo arm
(7.5%). These findings suggested that the
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one-step dose increase was appropriate for
treatment initiation [18].
In the open-label GetGoal-X study, 639
patients with type 2 diabetes inadequately
controlled with metformin were randomised to
lixisenatide 20 lg OD or exenatide 10 lg BD. Five
patients were excluded and the analysis
population comprised lixisenatide 20 lg OD
(n = 318) or exenatide 10 lg BD (n = 316), with
a main 24-week treatment period followed by an
extension of at least 52 weeks [12]. Lixisenatide
achieved the primary endpoint of non-
inferiority to exenatide for the reduction in
HbA1c from baseline; the least squares (LS)
mean ± SE change from baseline with
lixisenatide was -0.79% ± 0.05 and -0.96%
± 0.05 with exenatide (LS mean difference,
0.17%; 95% CI, 0.033–0.297%). This fulfilled
the pre-specified non-inferiority criterion based
on the upper CI limit of B0.4 %; the stricter CI
margin of 0.3% more recently recommended by
the European Medicines Agency (EMA) was met
in the modified intention-to-treat population.
Improvements in mean FPG and the proportions
of patients achieving HbA1c\53 mmol/mol (7%)
were similar between the treatments. Both
treatments were associated with body-weight
reductions—LS mean ± SE change from
baseline with lixisenatide OD was -2.96 ± 0.23
and -3.98 ± 0.23 kg with exenatide BD.
The overall incidence of adverse events was
similar between the two treatments, but with
numerically fewer adverse events leading to
discontinuation with lixisenatide (10.4% vs.
13.0% with exenatide), and fewer premature
discontinuations overall with lixisenatide
(12.9% vs. 14.2% with exenatide). The
incidence of nausea was lower in patients
receiving lixisenatide OD than in those who
received exenatide twice per day (24.5% vs.
35.1%, respectively, p\0.05). Fewer patients
experienced episodes of symptomatic
hypoglycemia with lixisenatide than exenatide
(2.5% vs. 7.9%; p\0.05; Fig. 3). This study
demonstrated that lixisenatide was non-
inferior to exenatide in improving glycemic
control in patients with type 2 diabetes
insufficiently controlled on metformin, but
may result in fewer hypoglycemic episodes




GetGoal-S randomised 859 patients with longer
duration diabetes (mean duration of
8.0–8.5 years) who were inadequately
controlled on an SU (85% were receiving
metformin in addition to their SU therapy at
baseline) to lixisenatide 20 lg OD or placebo for
24 weeks, with an optional extension of
52 weeks [21]. Of note, the study enrolled a
different ethnic mix to most other GetGoal
studies with 45% of patients being of Asian
origin.
Fig. 3 In the GetGoal-X study, patients experienced a
reduced incidence of nausea and a lower proportion of
patients experienced hypoglycemia with lixisenatide OD
versus exenatide BD [12]
374 Diabetes Ther (2014) 5:367–383
Lixisenatide significantly reduced HbA1c
compared with placebo (-0.85% vs. -0.10%;
p\0.0001) at 24 weeks; it also significantly
improved 2-h PPG, FPG, body weight and the
proportion of patients achieving HbA1c
\53 mmol/mol (7%) compared with placebo.
Higher rates of nausea and vomiting with
lixisenatide were recorded compared with
placebo. Symptomatic hypoglycemia was not
different between lixisenatide and placebo
(15.3% vs. 12.3%; p = NS) [21].
Patients Inadequately Controlled
on Thiazolidinediones
GetGoal-P assessed the addition of lixisenatide
to therapy in patients inadequately controlled
on C30 mg/day of pioglitazone (with or without
metformin) [22]. A total of 484 patients with a
mean duration of diabetes of 8.1 years were
randomised to receive lixisenatide 20 lg OD
(n = 323) or placebo (n = 161) with a two-step
dose increase, in combination with
pioglitazone, for the main double-blind
treatment period of 24 weeks, followed by a
variable double-blind extension of at least
52 weeks. Around 81% of patients were using
metformin at screening.
Lixisenatide significantly reduced HbA1c
from baseline to week 24 compared with
placebo (LS mean reduction of -0.90% vs.
-0.34%; p\0.0001) and significantly greater
proportions of patients receiving lixisenatide
achieved HbA1c goals of B48 mmol/mol (6.5%)
and \53 mmol/mol (7.0%) compared with
placebo [22]. Efficacy was maintained in the
extension period (HbA1c reduced by 1.1%
(lixisenatide) and 0.6% (placebo) at week 76).
Lixisenatide significantly improved FPG levels.
There was no significant reduction in body
weight compared with placebo. Significantly
fewer lixisenatide-treated patients required
rescue therapy compared with placebo-treated
patients. Lixisenatide was well tolerated with
similar rates of symptomatic hypoglycemia in
both groups (3.4% with lixisenatide vs. 1.2%
with placebo) [22]. This study demonstrated
that the addition of lixisenatide to pioglitazone
therapy significantly improved glycemic
control with a low risk of hypoglycemia and
good tolerability.
Patients Inadequately Controlled on Basal
Insulin
GetGoal-L-Asia randomised 311 patients with
long-duration diabetes (mean 13.9 years) who
were inadequately controlled on basal insulin
to lixisenatide 20 lg OD (n = 154), or placebo
(n = 157) for 24 weeks [14]. All patients
continued treatment throughout the study
with their established doses of basal insulin
with or without SU. Approximately 70% of
patients were receiving an SU at screening.
Around 60% of patients were receiving
insulin glargine, 27% were receiving insulin
detemir and 13% were receiving NPH insulin
[14]. This study was conducted in Japan,
South Korea, Taiwan and the Philippines,
where patients with type 2 diabetes have a
number of distinct features, including a
relatively low body mass index (BMI) (in
this study a mean of 25.3 kg/m2) and tend
to have reduced b cell function compared
with Western subjects.
Lixisenatide significantly improved HbA1c
levels compared with placebo by 24 weeks (LS
mean reduction of -0.88%, 95% CI -1.116,
-0.650; p\0.0001) and significantly more
patients achieved HbA1c targets with
lixisenatide than placebo [14]. Their long
duration of diabetes suggests that these
patients would have minimal insulin secretion
capacity remaining and, therefore, it will be of
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interest to see the glycemic reductions stratified
by duration, with the expectation that those
with shorter duration will experience better
glycemic improvement. Lixisenatide
significantly improved 2-h PPG levels, reduced
glucose excursions and 7-point self-measured
plasma glucose (SMPG) levels compared with
placebo, as well as significantly improving FPG
and lowering the daily insulin requirement. The
PPG reduction apparent after breakfast was
extremely marked (LS mean difference of
-7.83 mmol/L). There was a small but
significantly greater reduction in daily basal
insulin dose with lixisenatide than placebo
(–1.39 ± 0.46 vs –0.11 ± 0.44 U, p = 0.0019).
Discontinuation due to adverse events was
higher with lixisenatide than placebo (9.1%
vs. 3.2%, respectively), as was symptomatic
hypoglycemia (42.9% vs. 23.6%) although
there was no difference compared with
placebo in those patients not receiving SU
(32.6% with lixisenatide vs. 28.3% with
placebo). There were no cases of severe
hypoglycemia [14].
GetGoal-L randomised 496 patients
inadequately controlled on basal insulin and
metformin to lixisenatide 20 lg OD or placebo
for 24 weeks with a double-blind extension of at
least 52 weeks [15]. Patients were randomised in
a 2:1 ratio to lixisenatide (n = 329) or placebo
(n = 167). The mean duration of diabetes was
approximately 12.5 years, and 79% of patients
were using metformin at screening. Patients had
been receiving basal insulin for 3.1 years on
average, with 50% taking insulin glargine and
the majority of the remainder taking NPH
insulin.
Addition of lixisenatide to basal insulin
resulted in significant improvements in
glycemic control compared with placebo, with
an LS mean HbA1c reduction of -0.4% (95% CI
-0.6, -0.2; p = 0.0002) [15]. Significantly, more
lixisenatide-treated patients achieved HbA1c
goals than placebo-treated patients. There were
significant improvements in 2-h post-breakfast
PPG (LS mean difference of -3.8 mmol/L; 95%
CI -4.7, -2.9; p\0.0001), 2-h post-breakfast
glucose increment and average 7-point SMPG
with lixisenatide compared with placebo.
Patients receiving lixisenatide lost an average
of 1.3 kg of weight compared with those
receiving placebo (p\0.0001). Dose change of
basal insulin by week 24 was greater with
lixisenatide than placebo (–5.6 vs. –1.9 units/
day, LS mean change -3.7 units/day;
p = 0.012). There was a non-significant
increase in the incidence of symptomatic
hypoglycemia in patients treated with
lixisenatide compared with placebo (26.5% vs.
21.0%). There was a low rate of discontinuation
due to adverse events with lixisenatide of (7.6%
vs. 4.8% with placebo). These results
demonstrated the feasibility of adding a GLP-
1R agonist to those mainly North American and
Western European patients not achieving target
glycemic control on insulin [15].
In GetGoal-Duo-1, patients with inadequate
glycemic control on metformin (average HbA1c
of 70 mmol/mol [8.6%]) were initiated and
optimized on insulin glargine by titration to a
target FPG range of 4.4–5.6 mmol/L over a
12-week period (study design shown in Fig. 4)
[16]. Patients not achieving target HbA1c of
53 mmol/mol (7%) and with SMPG B7.8 mmol/
L (n = 446) were randomised to lixisenatide OD
or placebo; both insulin glargine and
metformin were continued. SU therapy was
stopped at randomisation, and 12% of patients
were receiving a thiazolidinedione (TZD).
Patients had a mean duration of diabetes of
9.2 years.
The lixisenatide group experienced a
significant improvement in glycemic control
compared with placebo, with an LS mean
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difference of -0.3% (p\0.0001) between
lixisenatide and placebo and more lixisenatide
patients achieved target glycemic control (56%
vs. 39%, p = 0.0001) [16]. Addition of
lixisenatide to insulin significantly improved
2-h PPG (mean reduction of -3.2 mmol/L vs.
placebo, p\0.0001), and resulted in a mean
difference in body weight of -0.9 kg compared
with placebo (p = 0.0012). Insulin glargine dose
increased more in the placebo group (?3.1 units
per day and ?5.3 units for lixisenatide and
placebo groups, respectively, p = 0.03). The
most common adverse events were mild and
transient nausea and vomiting. Symptomatic
hypoglycemia occurred in 22.4% of the
lixisenatide-treated patients and 13.5% of
those receiving placebo [16].
Cardiovascular Outcome Trial
A large, cardiovascular outcomes’ study (The
Evaluation of LIXisenatide in Acute coronary
syndrome (ELIXA) study is ongoing [25], and
complies with US Food and Drug
Administration (FDA) guidance that requires
pharmaceutical manufacturers to demonstrate
that new drugs for type 2 diabetes do not
increase the risk of cardiovascular events [26].
Although the FDA has no requirement for the
investigational drug to show superiority to
placebo, ELIXA is designed to demonstrate
that lixisenatide reduces cardiovascular
morbidity and mortality in patients with type
2 diabetes who have recently experienced an
acute coronary syndrome event. Patients have
been randomised, double-blind, to receive
lixisenatide 20 lg OD or placebo. This event-
driven study has an estimated enrollment of
6,000 patients and will run until the last patient
has been followed up for at least 10 months; the
median follow-up is estimated to be nearly
2 years. The primary endpoint is the time to
the first occurrence of a primary cardiovascular
event (the composite of cardiovascular death,
Fig. 4 Study design of GetGoal-Duo-1 [16]. FPG Fasting plasma glucose, TZD thiazolidinedione, SU sulphonylurea
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non-fatal myocardial infarction, non-fatal
stroke and hospitalization for unstable
angina). The study is one of four
cardiovascular outcomes’ studies ongoing with
GLP-1R agonists; ELIXA is expected to be
reported in 2014/2015 [27].
DISCUSSION
To date, the clinical development program
suggests that lixisenatide has an appropriate
pharmacodynamic action, with reductions in
blood glucose, in particular marked reductions
in PPG, manifesting as improvements in
glycemic control, a beneficial effect on body
weight, and with limited risk of hypoglycemia
with 20 lg OD dosing.
Reductions in HbA1c with lixisenatide from
baseline were consistent across the GetGoal
programme, with the main efficacy outcome
met in all studies. The reductions from baseline
in HbA1c ranged from -0.7% to -1.0%
(Table 2). These reductions appear slightly
lower than those reported with liraglutide,
which may reflect differences in baseline
characteristics, including HbA1c, or differences
in pharmacodynamics such as the more
pronounced effect that long-acting GLP-1R
agonists exert on FPG [9]; however, it is
difficult to make indirect comparisons across
studies. The randomised comparison of
lixisenatide OD with exenatide BD showed
lixisenatide was non-inferior to exenatide and
with similar numbers of patients achieving
target HbA1c of 53 mmol/mol (7%) (around a
half in each treatment group) [12], but this was
achieved with threefold fewer symptomatic
hypoglycemic events and with better
gastrointestinal tolerability than exenatide BD.
Discontinuations for adverse events were
consistently low, ranging from 2.5% to 10.4%
across the program (Table 3).
Except for GetGoal-Mono Japan, the
GetGoal studies were 12–24 weeks in duration
with longer, safety-orientated study extensions
of at least 1 year planned in six trials (GetGoal-
F1, -M, -X, -S, -P and -L). Long-term efficacy data
reported so far (from GetGoal-P and GetGoal-
F1) suggest that the glycemic improvement
with lixisenatide is maintained, with good
tolerability during long-term treatment and no
increased hypoglycemia risk versus placebo [18,
22].
Lixisenatide treatment had a consistent,
pronounced effect on PPG [14–18, 21],
reflecting the rapid increase in plasma levels
after injection that leads to delayed gastric
emptying and delayed systemic glucose
absorption, which manifest as blunted post-
meal glucose excursions [9]. Long-acting GLP-
1R agonists do not reduce PPG to the same
extent and do not exert the same effect on
gastric motility after long-term use as short-
acting agonists [9]. Studies of gastric emptying
suggest that long-acting agonists are subject to
desensitization/tachyphylaxis of the effect,
whereas short-acting agonists such as
lixisenatide continue to inhibit gastric
emptying even after repeated dosing [9]. The
pharmacodynamic differences with liraglutide
were shown in the phase II comparison, in
which lixisenatide OD had a significantly
greater PPG-lowering effect than liraglutide
OD after a standardized breakfast test in
patients with type 2 diabetes [11]. This was
associated with greater reductions in
postprandial insulin secretion than liraglutide,
which is consistent with slowing of gastric
emptying. In addition, lixisenatide markedly
and significantly suppressed glucagon secretion
compared to liraglutide.
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12 361 1 8.1 -0.9 -2.0
2 8.0 -0.7 -2.0
PBO 8.1 -0.2 -1.6
GetGoal-Mono
Japan [13]
None R, OL 24 69 1 8.2 -0.7 -0.4
2 8.2 -1.0 -1.1
GetGoal-M [19] Metformin R, DB,
PC
24 680 AM 8.0 -0.9 -2.0
PM 8.1 -0.8 -2.0
PBO 8.1 -0.4 -1.6
GetGoal-M-Asia
[20]
Metformin ± SU R, DB,
PC
24 391 1 8.0 -0.8 -1.5
PBO 7.9 -0.5 -1.2
GetGoal-F1 [18] Metformin R, DB,
PC
24 482 1 8.0 -0.9 -2.6
2 8.1 -0.8 -2.7
PBO 8.0 -0.4 -1.6
GetGoal-X [12] Metformin R, OL,
CC
24 634 2 8.0 -0.8 -3.0
EXE 8.0 -1.0 -4.0
GetGoal-S [21] SU ± metformin R, DB,
PC
24 859 2 8.3 -0.9 -1.8
PBO 8.2 -0.1 -0.9
GetGoal-P [22] PIO ± metformin R, DB,
PC
24 484 2 8.1 -0.9 -0.2
PBO 8.1 -0.3 ?0.2
GetGoal-L [15] Insulin ± metformin R, DB,
PC
24 496 2 8.4 -0.7 -1.8
PBO 8.4 -0.4 -0.5
GetGoal-L-Asia
[14]
Insulin ± SU R, DB,
PC
24 311 2 8.5 –0.8 -0.4




± SU ± TZD
R, DB,
PC
24 446 2 7.6 -0.7 ?0.3
PBO 7.6 -0.4 ?1.2
D is from baseline to study end
AM Morning, CC comparator controlled, DB double-blind, EXE exenatide, OL open-label, PBO placebo, PC placebo-
controlled, PIO pioglitazone, PM evening, R randomised, SU sulphonylurea, TZD thiazolidinedione, EXE exenatide 10 lg
twice daily
a Analysis population
b Dosing: 1, one-step dose increase; 2, two-step dose increase; AM or PM dosing; pooled placebo values
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There is an increased interest in addressing
the glycemic needs of patients not achieving
target despite basal insulin therapy.
Traditionally, postprandial hyperglycemic
excursions have been addressed by initiating
rapid-acting insulin at mealtimes. This insulin
intensification requires additional plasma
glucose monitoring and is frequently
associated with body weight gain and a risk of
hypoglycemia. The three studies with
Table 3 Incidence of selected gastrointestinal adverse events during the GetGoal phase III study programme
Study Dosinga Nausea (%) Vomiting (%) Discontinuationsb (%)
GetGoal-Mono [17] 1 20.2 6.7 2.5
2 24.2 7.5 4.2
PBO 4.1 0 0.8
GetGoal-Mono Japan [13] 1 50.0 2.8 11.1
2 36.4 12.1 9.1
GetGoal-M [19] AM 22.7 9.4 7.1
PM 21.2 13.3 5.5
PBO 7.6 2.9 1.2
GetGoal-M-Asia [20] 1 16.3 7.7 8.7
PBO 2.6 1.0 5.1
GetGoal-F1 [18] 1 26.1 11.8 5.6
2 35.4 15.5 8.1
PBO 4.4 0 2.5
GetGoal-X [12] 2 24.5 10.1 10.4
EXE 35.1 13.3 13.0
GetGoal-S [21] 2 25.3 8.7 9.8
PBO 7.0 3.5 4.9
GetGoal-P [22] 2 23.5 6.8 6.5
PBO 10.6 3.7 5.0
GetGoal-L [15] 2 26.2 8.2 7.6
PBO 8.4 0.6 4.8
GetGoal-L-Asia [14] 2 39.6 18.2 9.1
PBO 4.5 1.9 3.2
GetGoal-Duo-1 [16] 2 27.4 9.4 8.5
PBO 4.9 1.3 3.6
AM Morning or PM evening, PBO pooled placebo values, EXE exenatide (10 lg twice daily)
a Dosing: one-step dose increase; two-step dose increase
b Due to treatment-emergent adverse events
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lixisenatide have described the efficacy and
safety profile of lixisenatide add-on to basal
insulin in more than 1,200 patients, and have
demonstrated that lixisenatide offers a
treatment option that may be particularly
suited to these patients [14–16]. Lixisenatide
lowered HbA1c with beneficial effects on body
weight and minimal hypoglycemic risk. EASD
and ADA guidelines support this approach of
the addition of a GLP-1R agonist to basal
insulin, when necessary [24].
Antibody formation was expected in the
studies, as has been found in studies of
exenatide [27]. In the GetGoal-Mono study,
56–60% of patients developed anti-lixisenatide
antibodies, with no apparent effect on efficacy
or safety [17]. This proportion of antibody-
positive patients is roughly similar to that
shown in studies with exenatide BD and QW
[28], suggesting that antibody formation with
lixisenatide is unlikely to impact on efficacy or
safety outcomes.
In addition to its efficacy, lixisenatide has a
number of properties which improve its ease of
use. Lixisenatide has a simple one-step dose
increase and a single maintenance dose of 20 lg
OD for all patients. This dosing regimen is
simplified further with two fixed-dose pens,
each supplying 14 doses. The 10 lg pen is used
for 2 weeks for the initiation phase, and the
20 lg pen is used for the maintenance dose
thereafter.
A fixed-ratio combination of lixisenatide and
insulin glargine is under development
(‘LixiLan’). The phase III program comprises
two studies, LixiLan-O and LixiLan-L, and is
planned to enroll more than 1,800 patients with
inadequate glycemic control on oral anti-
diabetic drugs or not at target on basal insulin
[29]. The OD dosing delivered in a single pen
may offer an attractive treatment escalation
pathway for patients with inadequate glycemic
control. Lixisenatide offers an important add-
on option to patients as the diabetes treatment
paradigm moves to individualizing patient care
[24].
The ELIXA trial is ongoing and may be the
first GLP-1 cardiovascular outcomes’ study to
report [25]. The effects of GLP-1R agonists
beyond their glucose-lowering activity are
numerous, and include changes in blood
pressure, endothelial function, body weight,
cardiac metabolism, lipid metabolism, left
ventricular function, atherosclerosis, and the
response to ischemia–reperfusion injury [25].
The findings of ELIXA, if they confirmed
cardiovascular protection, may open a new
avenue for cardiovascular risk reduction in
type 2 diabetes.
CONCLUSION
Lixisenatide is the latest addition to the GLP-1R
agonist class of treatments for type 2 diabetes.
Although the fourth agent to be licensed, its
distinct pharmacodynamic action with marked
effects on PPG supports the effective glycemic
management of patients with inadequate
control on basal insulin, an approach that has
been validated in three phase III clinical trials.
This, coupled with patient-centric properties—
once-daily dosing, a one-step increase to a
single maintenance dose, and a lower
acquisition cost—suggest lixisenatide is an
important additional treatment option in type
2 diabetes.
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